Biomedical researchers continue to make significant efforts to describe considerations for clinical safety assessment of oncology products. There is a consistent approach to characterization of the preclinical safety profile that requires consideration of a number of factors. Some of these factors include clinical application, drug attributes, and material production.
oncology ... [Show full abstract] products;
anti-drug antibody response;